Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00743379 · ClinicalTrials.gov registry record · Phase 1
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
A Phase 1 study, sponsored by Threshold Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 71
- Enrollment target
NCT00743379 is a Phase 1 study that has completed, run by Threshold Pharmaceuticals. The registered enrollment target is 71 participants.
The verdict
NCT00743379, a Phase 1 study, has completed, sponsored by Threshold Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 71 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if TH-302, in combination with A) Gemcitabine, or B) Docetaxel or C) Pemetrexed methotrexate, are safe and effective in the treatment of Pancreatic Cancer, Castrate-resistant Prostate Cancer, and Non-small Cell Lung Cancer, respectively.
Interventions
- DRUG TH-302
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2008-08 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00743379
The ClinicalTrials.gov registry entry for NCT00743379 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Threshold Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TH-302 is the first listed.
NCT00743379 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00743379 about?
NCT00743379 is a clinical study titled "Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors". The purpose of this study is to determine if TH-302, in combination with A) Gemcitabine, or B) Docetaxel or C) Pemetrexed methotrexate, are safe and effective in the treatment of Pancreatic Cancer, Castrate-resistant Prostate Cancer, and Non-small Cell Lung Cancer, respectively.
What is the current status of trial NCT00743379?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2008-08. Estimated completion is 2014-03.
What interventions are being tested in trial NCT00743379?
The interventions under investigation include: TH-302 (DRUG).
Who is sponsoring clinical trial NCT00743379?
This trial is sponsored by Threshold Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.